Year Founded
2002
Ownership
Public
Employees
~1000
Stage
Commercial
Modalities
Small molecule

Intercept Pharmaceuticals General Information

Lead product Ocaliva approved for PBC in US and EU. Phase 3 REGENERATE trial for NASH met primary endpoint but received CRL from FDA in June 2020. Planning NDA resubmission by end of 2021.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
New York, NY
United States

Drug Pipeline

obeticholic acid
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Intercept Pharmaceuticals's pipeline data

Book a demo

Key Partnerships

TES Pharma, Professor Roberto Pellicciari

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Intercept Pharmaceuticals Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Intercept Pharmaceuticals's complete valuation and funding history, request access »